Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

SensoDetect AB Confirms receipt of license payments and announces successful installation and testing of AI software in China

SensoDetect
Read the release

SensoDetect AB (Spotlight Stock Market: SDET) is pleased to confirm that all license payments from its joint venture, Beijing Mind Exploration Medical Technology Co., Ltd., have been received in full and on time. This marks another significant milestone in the collaboration and commercialization of SensoDetect's BERA 4.2 system and its next-generation AI-driven diagnostic platform in China.

The company further announces that the AI software has now been successfully installed and activated within the joint venture's operational framework in Beijing. The first testing series has shown very promising results, confirming that the system can now perform the entire neurophysiological test in less than 5 minutes and 30 seconds, a substantial improvement in speed and efficiency.

Even though the system processes an extremely large amount of neurophysiological data, the AI calculations can be completed in under 10 seconds - either locally on the device or through secure cloud computation. This represents a major technological leap forward, significantly improving scalability, accessibility, and reliability for both clinical and research use.

"We are very pleased to confirm that all financial commitments from our Chinese partners have been fulfilled in full and that the AI system is now live and performing beyond expectations," says Per-Anders Hedin, CEO of SensoDetect AB. "The early test results are highly encouraging and demonstrate the strength of our technology to redefine clinical diagnostics by making it faster, smarter, and more efficient than ever before."

The AI module represents the next major evolution of SensoDetect's proprietary BERA (Brainstem Evoked Response Audiometry) technology, combining advanced signal processing with modern machine learning. With the system now operational, the joint venture will move forward with extended clinical validation, NMPA regulatory preparations, and scaling for production.

This progress follows the recently completed initial investment round in the joint venture, strengthening both its financial and technological base for a large-scale launch in the Chinese market.

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.